These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 2480856)

  • 1. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.
    Myerburg RJ; Kessler KM; Cox MM; Huikuri H; Terracall E; Interian A; Fernandez P; Castellanos A
    Circulation; 1989 Dec; 80(6):1571-9. PubMed ID: 2480856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of ventricular arrhythmias in children without structural heart disease with class IC agents as guided by invasive electrophysiology.
    Case CL; Gillette PC
    Am J Cardiol; 1990 Nov; 66(17):1265-6. PubMed ID: 2122708
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk factors for the development of proarrhythmic events.
    Morganroth J
    Am J Cardiol; 1987 Apr; 59(11):32E-37E. PubMed ID: 3107364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.
    Au PK; Bhandari AK; Bream R; Schreck D; Siddiqi R; Rahimtoola SH
    J Am Coll Cardiol; 1987 Feb; 9(2):389-97. PubMed ID: 2433319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
    Stramba-Badiale M; Lazzarotti M; Facchini M; Schwartz PJ
    Am Heart J; 1994 Nov; 128(5):973-82. PubMed ID: 7524295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
    Pratt CM
    Am J Cardiol; 1990 Feb; 65(8):51D-55D; discussion 68D-71D. PubMed ID: 1689536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.
    Feld GK; Chen PS; Nicod P; Fleck RP; Meyer D
    Am J Cardiol; 1990 Aug; 66(3):378-83. PubMed ID: 2114784
    [No Abstract]   [Full Text] [Related]  

  • 19. [Combination anti-arrhythmic drug therapy].
    Lüderitz B; Jung W; Manz M
    Z Kardiol; 1992; 81 Suppl 4():157-61. PubMed ID: 1283933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.